Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDH2 | P40926 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709669 | 0.86 | ALDH1A1 (0.64) | MDH2ALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL591695 | 0.82 | ALDH1A1 (0.58) | ALDH1A1MEN1CYP1A2KMT2AHTT | |
| SCHEMBL11246680 | 0.80 | MDH2 (0.68) | MDH2ALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL2976313 | 0.80 | ALDH1A1 (0.65) | MDH2ALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL2974546 | 0.78 | ALDH1A1 (0.62) | MDH2ALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL591684 | 0.77 | ALDH1A1 (0.50) | MDH2ALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL18589525 | 0.76 | CYP1A2 (0.64) | MDH2ALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL30075344 | 0.76 | MAPT (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL590922 | 0.76 | MAPT (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2050601 | 0.75 | CYP1A2 (0.59) | MDH2ALDH1A1HPGDSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | MDH2 2543/4885ALDH1A1 717/4885HPGD 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.